Featured Article
Three-Drug Combination Remodels Immune Environment in Gastric Cancer
Researchers studying 30 patients with advanced gastric cancer found that regorafenib, nivolumab and chemotherapy produced a 73% objective response rate while increasing tumor-reactive T cells and reducing several immunosuppressive cell populations.
